Cargando…

A promising strategy against SARS-CoV-2: pyrimidine inhibitors synergize with nucleoside analogues

Detalles Bibliográficos
Autores principales:	Min, Long, Sun, Qiu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Research Highlight
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8922063/ https://www.ncbi.nlm.nih.gov/pubmed/35292618 http://dx.doi.org/10.1038/s41392-022-00956-6

Ejemplares similares

Analogues of Pyrimidine Nucleosides as Mycobacteria Growth Inhibitors
por: Alexandrova, Liudmila A., et al.
Publicado: (2022)

Promising inhibitors targeting M(pro): an ideal strategy for anti-SARS-CoV-2 drug discovery
por: Chen, Yi, et al.
Publicado: (2020)

A bivalent recombinant vaccine: a promising strategy against both SARS-CoV-2 variants and wild type of the virus
por: Wang, Junzhi
Publicado: (2021)

Circular RNA vaccine, a novel mRNA vaccine design strategy for SARS‐CoV‐2 and variants
por: Su, Peng, et al.
Publicado: (2022)

FXR inhibition: an innovative prophylactic strategy against SARS-CoV-2 infection
por: Li, Zhe, et al.
Publicado: (2023)

Targeting the entry step of SARS-CoV-2: a promising therapeutic approach
por: Li, Jing, et al.
Publicado: (2020)

A booster with SARS-CoV-2 vaccines: protection against Omicron infection
por: Hu, Yuehong, et al.
Publicado: (2022)

Opsonizing antibodies mediated SARS‐CoV‐2 entry into monocytes leads to inflammation
por: Yao, Tong, et al.
Publicado: (2022)

Timing vaccination against SARS-CoV-2
por: Barnoud, Coline, et al.
Publicado: (2021)

Targeting SARS-CoV-2 Polymerase with New Nucleoside Analogues
por: Daikopoulou, Vasiliki, et al.
Publicado: (2021)

How will previous infection or current vaccination strategies protect us from future SARS‐CoV‐2 variant infections?
por: Monteiro, Olivia
Publicado: (2022)

Anti‐flavivirus Activity of Different Tritylated Pyrimidine and Purine Nucleoside Analogues
por: McGuigan, Christopher, et al.
Publicado: (2016)

A promiscuous interaction of SARS-CoV-2 with bacterial products
por: Carissimo, Guillaume, et al.
Publicado: (2020)

Virtual Issue on SARS-CoV-2: Evolution of a Pandemic
por: McGrath, Casey
Publicado: (2023)

Landscapes of SARS-CoV-2-reactive CD8(+) T cells: heterogeneity of host immune responses against SARS-CoV-2
por: Koh, June-Young, et al.
Publicado: (2021)

Autoimmunity and SARS‐CoV‐2 infection: Unraveling the link in neurological disorders
por: Latorre, Daniela
Publicado: (2022)

Synthesis of Cyclobutane Analogue 4: Preparation of Purine and Pyrimidine Carbocyclic Nucleoside Derivatives
por: Hasaneen, Noha, et al.
Publicado: (2019)

Kidney injury molecule-1: a novel entry factor for SARS-CoV-2
por: Wan, Cheng, et al.
Publicado: (2021)

In search for novel strategies towards neuroprotection and neuroregeneration: is PPARα a promising therapeutic target?
por: Moreno, Sandra, et al.
Publicado: (2015)

Janus kinase signaling as risk factor and therapeutic target for severe SARS‐CoV‐2 infection
por: Solimani, Farzan, et al.
Publicado: (2021)

STING, a critical contributor to SARS-CoV-2 immunopathology
por: Li, Heyu, et al.
Publicado: (2022)

A two‐step infection model: From SARS‐CoV‐2 entry and trafficking to egress and spread
por: You, Liting, et al.
Publicado: (2023)

Newly synthesized M(pro) inhibitors as potential oral anti-SARS-CoV-2 agents
por: Li, Lin, et al.
Publicado: (2021)

Antigen‐dependent multistep differentiation of T follicular helper cells and its role in SARS‐CoV‐2 infection and vaccination
por: Baumjohann, Dirk, et al.
Publicado: (2021)

Type I interferon signaling deficiency results in dysregulated innate immune responses to SARS‐CoV‐2 in mice
por: Ogger, Patricia P., et al.
Publicado: (2022)

TMPRSS2, a novel host-directed drug target against SARS-CoV-2
por: Keller, Christian, et al.
Publicado: (2022)

Level up for culture models - How 3D cell culture models benefit SARS-CoV-2 research
por: Häfner, Sophia Julia
Publicado: (2021)

SARS-CoV-2 sensory loss
por: York, Ashley
Publicado: (2022)

Sewer biofilms and SARS-CoV-2
por: Du Toit, Andrea
Publicado: (2023)

SURFing SARS-CoV-2 inhibition
por: Taglialegna, Agustina
Publicado: (2023)

Potential recombination between SARS-CoV-2 and MERS-CoV: calls for the development of Pan-CoV vaccines
por: Wang, Qiao, et al.
Publicado: (2023)

Compartmentalized immune responses and the local microbiota determine mucosal and systemic immunity against SARS-CoV-2
por: Buttenschön, Jonas, et al.
Publicado: (2022)

“Armed for the future Coronavirus pandemic”: a promising use of the multimeric SARS-CoV-2 receptor binding domain nanoparticle as a new Pan-Coronavirus vaccine
por: Kumar, Manoj, et al.
Publicado: (2021)

New strategy for COVID-19 vaccination: targeting the receptor-binding domain of the SARS-CoV-2 spike protein
por: Wang, Junzhi
Publicado: (2020)

New 5-Modified Pyrimidine Nucleoside Inhibitors of Mycobacterial Growth
por: Alexandrova, L.A., et al.
Publicado: (2010)

A CNS gateway for SARS-CoV-2
por: Yates, Darran
Publicado: (2021)

SARS-CoV-2 detected in olfactory neurons
por: Lemprière, Sarah
Publicado: (2021)

Super(antigen) target for SARS-CoV-2
por: Brown, Matthew, et al.
Publicado: (2021)

Cellular basis for SARS-CoV-2 infection
por: Baumann, Kim
Publicado: (2020)

SARS-CoV-2 nanobodies 2.0
por: Labroussaa, Fabien, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_pv6cghsakt0jb1ce4bnkeppq5h